Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus BACTOCILL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus BACTOCILL IN PLASTIC CONTAINER.
BACTOCILL vs BACTOCILL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity essential for peptidoglycan cross-linking.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
1-2 g intravenously every 4 hours.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
30-60 minutes (mean 40 min) in adults with normal renal function; prolonged to 7-10 hours in anuria. Clinical context: dosing interval adjustment required in renal impairment.
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Primarily renal (60-70% unchanged by tubular secretion and glomerular filtration); biliary/fecal excretion accounts for <30%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic